VANCOUVER, BRITISH COLUMBIA--(Marketwire - November 13, 2007) - Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX VENTURE: PGA) announced today a poster entitled, “Evaluation of a New Host Derived Synthetic Antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis”, will be presented at the 5th International Meeting on Antimicrobial Chemotherapy in Clinical Practice (ACCP) to be held in Portofino, Italy on November 15-17, 2007. The poster presentation of in-vitro data (paper number 29) will be given by Dr. Eva Helmerhorst from Goldman School of Dental Medicine, Boston University.
